Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of a drug called rituximab used together with other drugs-prednisone,
etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of
standard chemotherapy for relapsed Acute Lymphoblastic Leukemia (ALL). Rituximab was approved
by the Food and Drug Administration in 1997. However, the use of rituximab with prednisone,
etoposide, and ifosfamide in pediatric patients with relapsed or refractory ALL is considered
experimental.
This study is for patients who have ALL in second or greater relapse, or in first relapse and
not responding to treatment.
The goals of this study are:
- To see if using rituximab with prednisone, etoposide, and ifosfamide is beneficial to
leukemia treatment
- To find out what side effects this combination of drugs can cause
A total of 15 participants (30 years old or younger) will be enrolled, over a period of 2
years.